Skip to main content
14 views

Semax

Nootropic peptide for cognitive enhancement and neuroprotection

Semax molecular structure

Overview

Semax is a synthetic brain-boosting peptide developed in Russia, derived from a fragment of ACTH (a hormone that regulates stress response). It's one of the most well-researched nootropics, approved in Russia for stroke recovery and cognitive disorders. **What makes it special?** Semax increases BDNF (brain-derived neurotrophic factor) — essentially "fertilizer" for your brain that promotes the growth of new neurons and strengthens existing connections. **What the research shows:** • Enhances memory, focus, and learning capacity • Provides neuroprotection against oxidative stress and ischemia • May help with stroke recovery and optic nerve diseases • Shows antidepressant-like effects in studies • Supports nerve regeneration **How it works:** Semax modulates dopamine and serotonin systems while boosting BDNF. Unlike stimulants, it enhances cognition without causing jitters or crashes. **Typical use:** Administered as a nasal spray (usually 0.1% solution) for rapid absorption into the brain. Effects typically felt within 15-20 minutes. **N-Acetyl Semax:** An enhanced version with better blood-brain barrier penetration and potentially stronger effects. **Important to know:** Approved in Russia but not FDA-approved in the US. Research is promising but mostly from Russian institutions. --- **Sources:** Ashmarin IP, et al. (1997) Neuroscience and Behavioral Physiology | Dolotov OV, et al. (2006) Neuroscience

Last reviewed: 2026-08-18

Identity & Aliases

Also known as

SemaxACTH(4-7) analogMet-Glu-His-Phe-Pro-Gly-ProN-acetyl semax heptapeptide

Status: Research compound - Neuropeptide (approved in Russia)

CAS80714-61-0
PubChem9811102

Full composition (formula, molecular weight, sequence) in Quick Facts →

Research Areas

Cognitive enhancementStroke rehabilitationPediatric ADHD (investigational)Neuroprotection

Available Evidence

Human

Semax is a registered drug in Russia used for cognitive disorders and stroke recovery, with clinical studies published largely in the Russian-language literature. Available English-indexed human data are limited, and the peptide is not FDA-approved. Controlled trials in pediatric ADHD and post-stroke cognitive recovery have been reported, mostly in Russian-language journals.

Animal

Rodent studies demonstrate semax upregulates BDNF and NGF expression, protects against experimental ischemia, and modulates hippocampal gene expression under acute stress (2021).

In Vitro

Cell-based studies report semax-induced increases in BDNF/NGF expression in neuronal and glial cultures.

Uncertain

Nootropic claims in healthy users remain largely unproven in Western-registered trials; the evidence base is dominated by Russian studies whose protocols and endpoints are not always independently verified.

Key Studies & Findings

1 studies

Benefits & Effects

24 documented

Memory improvement

anecdotal

Neuroprotection

anecdotal

Cognitive enhancement

anecdotal

Mood stabilization

anecdotal

Focus enhancement

anecdotal

Stress resilience

anecdotal

BDNF/NGF Modulation: 1.4-fold BDNF increase, 3-fold exon III BDNF mRNA

clinical

Stroke Rehabilitation: Accelerated functional recovery

clinical

Nootropic

Neuroprotection

Improves memory and attention

Stroke recovery.

Enhanced focus and concentration

anecdotal

ADHD symptom relief

anecdotal

Brain fog reduction

anecdotal

Stroke recovery support

anecdotal

Accelerated neurological function restoration

clinicalneuroprotection

Increased plasma BDNF levels

clinicalneurotrophic

Improved motor performance

clinicalmotor function

Anti-amyloid aggregation effects

preclinicalneuroprotection

Nootropic

Neuroprotection

Improves memory and attention

Stroke recovery.

Side Effects & Safety

8 reported

Minor side effects, good tolerability including in elderly

mildrare

Anticoagulant properties

mild

Nasal dryness

mildUncommon

Mild headache

mildUncommon

Restlessness

mildUncommon

Rare insomnia

severeRare

Minimal adverse events

mild

Mild side effect

mildCommon Reversible

Onset: Immediately

Management: Proper spray technique; saline rinse

Dose-dependent

Limitations & Open Questions

Most clinical evidence is published in Russian journals with limited English abstracts, which hampers independent verification. There are no FDA-reviewed trials, long-term safety data in Western populations are unestablished, and use for cognitive enhancement in healthy people is off-label.

Pharmacology

Administered intranasally (the registered Russian route); a short half-life requiring repeated dosing. Mechanism proposed via melanocortin receptor modulation with upregulation of BDNF/NGF and neuroprotective signaling.

Reported Research Dosing

Reported values from research literature and community protocols. Educational reference only — not a dosing recommendation or medical advice.

300-600 mcg 1-3x/day

Route: Intranasal
Half-life: Extended

Research Protocols

Cognitive enhancement (healthy adults)

Dose
300-600mcg
Frequency
1-2 times daily
Route
Intranasal spray/drops

Learning and memory support

Dose
600-900mcg
Frequency
2-3 times daily during study periods
Route
Intranasal spray/drops

Recovery from brain injury

Dose
900-1500mcg
Frequency
2-3 times daily
Route
Intranasal drops (clinical supervision)

Anti-fatigue cognitive support

Dose
400-800mcg
Frequency
Single morning dose
Route
Intranasal spray

Research/experimental protocols

Dose
250-1000mcg
Frequency
Variable based on study design
Route
Standardized intranasal delivery

Research protocols are for educational purposes only. Always consult qualified medical professionals.

Frequently Asked Questions

Is Semax FDA-approved?

No. It is a registered drug in Russia for cognitive and cerebrovascular disorders but is not approved by the FDA or EMA.

What is Semax made of?

It is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) derived from the ACTH(4-7) fragment, stabilized by a prolyl-glycyl-proline sequence.

Does Semax improve cognition?

Russian clinical studies report cognitive benefits in stroke and cognitive-disorder patients, but the evidence is mostly in Russian-language literature; no FDA-reviewed trials confirm cognitive enhancement in healthy people.

Research Citations

Related Resources

Quick Facts

Formula

C37H51N9O10S

Molecular Weight

813.93

Sequence

Met-Glu-His-Phe-Pro-Gly-Pro

Mechanism

ACTH analog with nootropic and neuroprotective effects

Safety Information

Research compound only in most countries. Limited long-term safety data available.

View All Peptides